

CURRICULUM VITAE: MASSIMILIANO MAZZONE

First name, LAST NAME: Massimiliano, MAZZONE
Place and Date of Birth: Torino, March 5th 1979
Nationality: Italian
Institute: Center for Cancer Biology, VIB, KU Leuven
Address: Campus Gasthuisberg, Herestraat 49, B-3000 Leuven (BE)
Phone: +32.16.37 32 13
Fax: +32.16.37.25.85
Orcid: 0000-0001-8824-4015
E-mail: massimiliano.mazzone@kuleuven.vib.be
Websites: <http://www.vibcancer.be/massimiliano-mazzone>
<http://www.vib.be/en/research/scientists/Pages/Massimiliano-Mazzone-Lab.aspx>
<http://www.kuleuven.be/wieiswie/en/person/00053986>



PERSONAL STATEMENT

Initially focusing on vascular biology, my research led to the characterization of a new endothelial cell phenotype during the perfusion of hypoxic tissues (Mazzone et al., Cell, 2009; Leite de Oliveira et al., Cancer Cell, 2012; Ehling et al., Circulation Res, 2019). From there, my research led initially to the characterization of a new endothelial cell phenotype during the perfusion of hypoxic tissues (Mazzone et al., Cell, 2009; Leite de Oliveira et al., Cancer Cell, 2012; Ehling et al., Circulation Res, 2019). Thereafter, my team has mainly studied the response of inflammatory cells to hypoxia (or to a cytokine surge) in order to restore blood flow in cancer and ischemia (Rolny et al., Cancer Cell, 2011; Casazza et al., Cancer Cell, 2013; Wenes et al., Cell Metabolism, 2016; Takeda et al., Nature, 2011; Hamm et al., EMBO Mol Med, 2013). We have been pioneering the concept that localization of tumor-associated macrophages (TAMs) is determinant for their pro-tumoral, angiogenic, immunosuppressive phenotype (Wenes et al., Cell Metabolism, 2016; Bieniasz-Krzywiec et al., Cell Metabolism, 2019; Casazza et al., Cancer Cell, 2013) and we have shown that specific inflammatory fingerprints can be exploited for disease detection and follow-up in cancer patients or can be tackled to improve disease response to targeted therapies (Hamm et al., Gut, 2016; Finisguerra et al., Nature, 2015). We have also extended our knowledge on macrophages to the metastatic niche (Celus et al., Cell Reports, 2017). We found that TAMs encountering hypoxic regions heavily adapt their metabolism; consequently they will enter in metabolic competition with other stromal components and this will affect their functions (Wenes et al., Cell Metabolism, 2016; Palmieri et al., Cell Rep, 2017; Menga et al., EMBO Mol Med, under final decision). Similarly, cancer cells under glucose or oxygen deprivation overcome cell death by remodeling their metabolic and oxygen-sensing machinery (Di Conza et al., Cell Rep, 2017a; Di Conza et al., Cell Rep, 2017b). My team has also contributed to the study of macrophages at the metastatic niche (Celus et al., Cell Reports, 2015). Finally, we have transferred our knowledge in cancer to other diseases such as inflammation, infections and tissue regeneration where immune cell responses are important to reestablish homeostasis (Takeda et al., Nature, 2011; Hamm et al., EMBO Mol Med, 2013; Finisguerra et al., Nature, 2015; Shang et al., Nature, in press). With all our findings, we made a step forward in the understanding of vessel remodeling, macrophage heterogeneity, cancer immune evasion and resistance to immunotherapy. The translation and valorization of my work is proven by ongoing clinical trials, two spin-offs, venture capital fundings for the foundation of a third spin-off, a prospective study, numerous industrial collaborations (more than ten), drug screening programs, and a diagnostic kit licensed out to a Belgian company.

EDUCATION

November 2006 to January 2009:

Postdoctoral Fellow, Vesalius Research Center, VIB, Catholic University of Leuven (KU Leuven), Belgium.

From November 1st 2002 to February 7th 2007:

PhD in Cell Science and Technology, Division of Molecular Oncology, IRCC, School of Medicine, University of Torino, Italy.

From September 1997 to July 2002:

Master (5-year course) in Medical Biotechnology (full marks and exceptional honors), School of Medicine, University of Torino, Torino, Italy.

From September 1992 to July 1997:

Scientific Lyceum (60/60 first class honors), Institute Marie Curie, Pinerolo, Torino, Italy.

RESEARCH EXPERIENCE & POSITIONS

ACADEMIC POSITIONS

From September 2018 to present:

Full Professor, Department of Oncology, KU Leuven, Leuven, Belgium.

From April 2019 to present:

Part-time Full Professor (Professore Straordinario), Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.

From October 2014 to September 2018:

Tenured, Associate Professor, Department of Oncology, KU Leuven, Leuven, Belgium.

From October 2009 to September 2014:

Assistant Professor (Tenure Track), Department of Oncology, KU Leuven, Leuven, Belgium.

RESEARCH POSITIONS

From October 2009 to present:

Head of the Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium (Junior Group Leader from March 2009 to September 2014; Group Leader from October 2014 to December 2017; Senior Group Leader from January 2018 to present).

From November 2006 to September 2009:

Postdoctoral Fellow, Vesalius Research Center, VIB-KU Leuven, Belgium.

Topics: oxygen sensors in mouse models of ischemia and cancer, validation of small molecules and antibodies in cancer. Supervisor: Prof. Peter Carmeliet.

From November 2002 to October 2006:

Ph.D. Student, Division of Molecular Oncology, IRCC, School of Medicine, University of Torino, Italy.

Topics: lentiviral vector-based gene-therapy strategies and validation of blocking antibodies in mouse models of cancer and metastasis, validation of recombinant proteins in mouse models of iatrogenic damage.

Supervisor: Prof. Paolo M. Comoglio.

From September 1999 to July 2002:

Undergraduate Student, Division of Molecular Oncology, IRCC, School of Medicine, University of Torino, Italy.

Topics: lentiviral vector-based gene-therapy strategies in mouse models of cancer and metastasis, study of hypoxia on metastatic behavior of cancer cells in vitro and in mice.

Supervisor: Prof. Maria Flavia Di Renzo, Dr. Paolo Michieli.

From June to November 1998:

Undergraduate Student, Molecular Biotechnology Center, School of Medicine, University of Torino, Italy.

Topics: generation and screening of transgenic mouse lines lacking for the gene Citron-Kinase (Citron K).

Supervisor: Prof. Guido Tarone, Dr. Ferdinando Di Cunto.

ACADEMIC ACTIVITY

Supervisor experience: training of 7 graduated and 9 enrolled PhD students (of which 3 obtained their Master Diploma at KU Leuven and 13 at different international Universities); 1 enrolled PhD student at the University of Torino (Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center), co-promoter of 2 enrolled PhD students (of which 1 at KU Leuven and 1 from the University of Aveiro); 12 completed and 2 enrolled post-docs; 51 bachelor and master thesis students (of which 18 from KU Leuven and 33 from 26 different international Universities); 13 visiting PhD students, 5 visiting post-docs, 2 visiting Professors. Serving on the thesis committee of 28 PhD students at KU Leuven (national and international) and twice as a President of the committee (chosen by the Rector of KU Leuven). External Jury Member and Advisor of 3 students from the University of Milano (European School of Molecular Medicine); 1 student from the University of Torino; 1 student from the VUB (Flemish University in Brussels); 2 students from ULB (Université Libre de Bruxelles, GIGA Institute and Gosellies Campus).

Track record of trainees Five of the post-docs in my lab (Y. Takeda, C. Roncal, S. Costa, A. Hamm, M. Pecqueux) have a position as Assistant Professor and/or group leader and/or resident surgeons, 3 of the post-docs (A. Casazza, R. Martin-Perez, E. Delamarre) are staff scientists in pharmaceutical companies, 2 others (P. Rouhikhorasani, AT Henze) are medical writers. Four of the 8 graduated PhD students moved to another European institution with a granted European or national fellowship, 1 is research professor in China, 1 moved to industry, 1 is junior group leader, 1 is a scientific writer.

Mentoring committees for tenure tracks:

- Dr. Ping-Chih Ho, Ludwig Cancer Center, University of Lausanne, CH
- Dr. Saverio Tardito, Beatson Institute, University of Glasgow, UK

Visiting Professorships:

- Dpt. of Biosciences, Biotechnologies & Biopharmaceutics, Bari University, IT (June-July 2019)

Board Memberships of Doctoral Schools:

- Doctoral School in Cancer, University of Leuven, BE (from 2009 till present)
- Doctoral School in Cardiovascular Medicine, University of Leuven, BE (from 2009 till 2017)
- Doctoral School in Molecular Medicine, University of Torino, IT (from 2020 till present)
- Doctoral School in Pharmacology, University of Padua, IT (from 2017 till present)
- Doctoral School in Biochemistry and Molecular Biology - Pegaso PhD of Tuscany, joining the three Universities of Florence, Siena and Pisa, IT (from 2019 to 2020)

Teaching duties in Summer schools:

- CBCS International Summer School on Cardiovascular Sciences, Nice, FR (June 16th-June 20th, 2013)
- CBCS International Summer School on Cardiovascular Sciences, Nice, FR (June 12th- June 16th, 2011)
- ESHRE International Summer School on Cancer, Leuven, BE (September 25th- September 26th, 2009)

Teaching duties in Doctoral schools:

- Biomedical Congress, KU Leuven, BE (April 23rd, 2013)
- SEMM PhD Course on “Cancer-associated inflammation” at IFOM-IEO, University of Milano, IT (April 2012)
- PhD Course at the School in Cardiovascular Medicine, KU Leuven, BE (March 2012)
- SEMM PhD Course on “Cancer-associated inflammation” at IFOM-IEO, University of Milano, IT (March 2011)
- Molecular and Developmental Genetics PhD Course at KU Leuven, BE (December 2010)
- DIMET PhD Course on “Tumor Microenvironment” at Milano-Bicocca University, Milano, IT (November 2010)
- Oncoforum PhD Course at the School in Cancer, Cancer Institute of Leuven (LKI), BE (May 2010)
- Interuniversity course on Angiogenesis to graduate students (MD) at the University of Brussels, BE (October 2008)

Teaching duties for undergraduate students:

- Course in Genome editing, stem cells, and tissue regeneration, Master in Medical Biotechnology, University of Torino, IT (from 2020)
- Course in Oncology, Master in Biomedical Science, KU Leuven, BE (from January 2007 to present)
- Course Cardiovascular Biology, Master Biomedical Science, KU Leuven, BE (from October 2011 to September 2017)
- Course in Cell Biology and Human Histology to nursing and physiotherapy undergraduate students, University of Torino, IT (from October 2004 to November 2006)

AWARDS & HONORS

November 2017: ERC Consolidator Grant

August 2016: ERC Proof-of-Concept

December 2015: Award Foundation AstraZeneca (Oncology), December 14th, Brussels

July 2015: Chiara D’Onofrio Award (Senior category) from the Foundation Chiara D’Onofrio and the Italian Association for Biophysics and Molecular Biology (Torino, July 1st)

November 2014: EMBO Young Investigator Award 2014

November 2014: André Vander Stricht-Emile Carpentier Prize, King Baudouin Foundation (Brussels, November 11th)

August 2012: ERC Starting Grant

May 2012: Lorini Award 2011, Foundation Andrea and Libi Lorini (Bovara Palace, Milano, May 7th)

September 2010: Prof. Karel-Lodewijk Verleysen Award, Belgian Royal Academy of Medicine

May 2010: Research Council Award 2010, KU Leuven

April 2010: Burgen Award, Academy of Europe

November 2009: Rimoux-Bartier Schenking Award for incurable diseases

May 2008: Science Award for the best abstract, 8th ESH conference on angiogenesis (Paris, May 9th-12th)

January 2007: Selected for the FEBS Long-Term Fellowship

December 2006: Selected for the EMBO Long-Term Fellowship

May 2005: Giulia Colletta Award, Italian Association for Cancer Research (AIRC)

LECTURES

NATIONAL INSTITUTIONAL SEMINAR SERIES

- March 2018:** Invited speaker, iTeos Therapeutics, Gosselies, BE (March 21st)
February 2018: Invited speaker, Stem Cell Institute, KU Leuven, BE (February 19th)
December 2017: Invited speaker, ULB, Campus de Charleroi, Gosselies, BE (December 22th)
November 2017: Invited speaker, GIGA Institute, Cancer Seminars, Liege, BE (November 24th)
September 2014: Invited speaker, PhD Symposium, VUB, Brussels, BE (September 11th-12th)
June 2011: Invited speaker, DMBR Seminars, University of Ghent, Ghent, BE (June 16th)
November 2009: Lecture on “Angiogenesis: from the bench side perspective”, Bordet Institute, Brussels, BE
September 2009: Lecture on “Invasion and metastasis” at the ESHRE School, Leuven, BE
October 2008: Lecture on ‘Angiogenesis and inhibitors’, University of Brussels, Brussels, BE
April 2006: PhD thesis dissertation, Dpt. for Transgene Technology and Gene Therapy, VIB, KU Leuven, BE

INTERNATIONAL INSTITUTIONAL SEMINAR SERIES

- November 2020:** Keynote Speaker, Symposium on Monocytes & Macrophages, Bordeaux, FR (November 27th)
May 2020: Invited Speaker, Symposium “Inflammation and Immunity”, University of Vienna, AT (May 11th-13th)
March 2020: Invited Speaker, ICGEB, Trieste, IT (March 23rd)
October 2019: Invited speaker, INSERM, Nice, FR (October 28th)
July 2019: Invited Speaker, Metabolism meets function – MBC, Torino, IT (July 19th)
June 2019: Invited speaker, CNIO, Madrid, ES (June 14th)
January 2019: First invited speaker by CRUK MI STAY committee, opening lecture, jointly at Cancer Research UK Manchester Institute and MRC, Manchester (January 17th). Aim of this seminar series is to expose junior scientists in helping them to become exposed to world-class research and to share with them successful career development stories.
December 2018: Invited speaker, IRCC, Institute for Cancer Research, Candiolo, Torino, IT (December 20th)
December 2018: Invited speaker, ReTuBi Final Scientific Symposia, IMM, Lisbon, PT (December 5th-7th)
November 2018: Invited speaker, Barts Cancer Institute, London, UK (November 6th)
September 2018: Invited speaker, INSERM, University of Bordeaux, FR (September 24th)
July 2018: Invited speaker, Department of Research, Diagnosis and Innovative Technologies, Regina Elena National Cancer Institute, Rome, IT (July 18th)
May 2018: Lola and John Grace Distinguished Lecture in Cancer Research, ISREC-EPFL, Lausanne, CH (May 24th)
March 2018: Invited speaker, San Raffaele Institute, Milano, IT (March 12th)
February 2018: Invited speaker, CCA, Cancer Center Amsterdam (joint AMC and VUmc), Noordwijkerhout, NL (February 15th-16th)
January 2018: Invited speaker, University of Padova, Department of Pharmacology, Padova, IT (January 19th)
July 2017: Keynote lecturer, Mini-Symposium, University of Nantes, FR (July 6th)
February 2017: Invited speaker, Novartis, Basel, CH (February 28th)
December 2016: Invited speaker, Cancer Research Centre of Lyon, FR (December 9th)
July 2016: Invited speaker, University Lausanne, CH (July 29th)
June 2016: Invited speaker, Istituto Oncologico Veneto, IRCCS, Padova, IT (June 6th)
May 2016: Invited speaker, Master Class Series, PARCC, INSERM, Paris, FR (May 27th)
March 2016: Invited speaker, MRC University of Edinburgh Centre for Inflammation Research Seminar Series, Edinburgh, UK (March 18th)
April 2015: Invited speaker, ICVS 2015 Spring Seminar Series, Minho University, Braga, PT (April 16th)
April 2015: Invited speaker, IMM (Instituto de Medicina Molecular), Lisbon, PT (April 13th)
December 2014: Invited speaker, University of Utrecht, NL (December 12th)
November 2014: Invited speaker, University of Groningen, Groningen, NL (November 6th)
October 2014: Invited speaker, DFKZ, Heidelberg, DE (October 22nd)
May 2014: Invited speaker, Biocenter, University of Oulu, Oulu, FI (May 27th)
February 2014: Invited speaker, University of Sheffield Medical School, Sheffield, UK (February 14th)
January 2014: Invited speaker, Netherlands Cancer Institute, NKI, Amsterdam, NL (January 17th)
August 2013: Invited speaker, Regeneron Pharmaceuticals, Tarrytown, New York, USA (August, 2nd)
May 2013: Invited speaker, MRC Research Centre, University of Cambridge, UK (May 7th)
April 2013: Invited speaker, Cancer Research Institute IRCC, Candiolo, Torino, IT (April 22nd)
May 2012: Invited speaker "Vascular Differentiation" Lecture series, DFKZ, Heidelberg, DE (May, 29th)
April 2012: Invited speaker, San Donato Institute, Milano, IT (April 17th, 2012)
December 2011: Invited speaker, IFOM-FIRC Institute of Molecular Oncology, Milano, IT (December, 16th)
March 2011: Invited speaker, Center for Molecular Biotechnology, Torino, IT (March 28th)
December 2010: Invited speaker, Cancer Research UK, Lincoln's Inn Fields, London, UK (December 7th)

November 2010: Invited speaker, San Raffaele Scientific Institute, Milano, IT (November, 19th)
October 2010: Invited speaker, Institute of Molecular Medicine, CNR, Rome, IT (October, 27th)
October 2010: Invited speaker, IFOM-FIRC Institute of Molecular Oncology, Milano, IT (October, 26th)
October 2010: Invited speaker, Cancer Research Institute IRCC, Candiolo, Torino, IT (October 25th)
April 2010: Invited speaker, Institute of Genetics and Biophysics, CNR, Naples, IT (April 19th)
February 2009: Invited speaker, Cornell University, New York, USA
September 2008: Invited speaker at the Erasmus Medical Center, Dpt. of Neurology, Rotterdam, NL
April 2006: PhD thesis dissertation, Vesalius Research Center, KU Leuven, BE
April 2006: PhD thesis dissertation, Dpt. of Molecular Genetics, NKI, Amsterdam, NL
April 2006: PhD thesis dissertation, Dpt. of Dev. Biol. and Stem Cell Res., Hubrecht Institute, Utrecht, NE

NATIONAL CONFERENCES

September 2014: Invited speaker, Interuniversity PhD Symposium, VUB, Brussels, BE (September 11th-12th)
April 2013: Invited speaker, Biomedical Conference, KU Leuven, BE (April 23rd)
February 2013: Invited speaker, VIB seminars annual meeting, Blankenberge, BE (February 7th)
September 2012: Invited speaker, SCIL Seminars, Stem Cell Institute, KU Leuven, BE (September 19th)
May 2011: Invited speaker, VIB Science Club, Leuven, BE (May 2nd)
February 2011: Invited speaker, Belgian Association for Cancer Research Annual Meeting, Liège, BE
May 2010: Keynote lecture at the Oncoforum, Doctoral School Cancer, Cancer Institute of Leuven, BE (May 27th)
January 2010: Invited speaker, Belgian Association for Cancer Research Annual meeting, Leuven, BE (January 21st)

INTERNATIONAL CONFERENCES

March 2021: Invited Speaker, French Dendritic Cell Society Meeting 2021, Lyon, FR (March 29th-30th)
March 2021: Invited Speaker, EMBO Conference, Sitges, Barcelona, ES (March 15th-17th)
November 2020: Invited Speaker, 33th Annual Conference of AICC “Dissecting metabolic circuitries in cancer cells and microenvironment: how to learn from bad lessons to develop new therapeutic opportunities”, Torino, IT (23th-24th November)
October 2020: Invited Speaker, ADELIS conference: ‘Metabolism in cancer : from reprogramming to therapeutic vulnerability’, Paris, FR (October 1st-2nd)
September 2020: Invited Speaker, Conference “Cancer Biology: from Basic to Translational Research”, Lisbon, PT (September 25th)
July 2020: Invited Speaker, 36th ISHR European Section Meeting, University of Torino, IT (30th June-3rd July)
July 2020: Invited speaker, third edition on ‘Metabolism meets function’, Florence, IT (July 20th)
June 2020: Invited Speaker, “Endothelial Cell Phenotypes in Health and Disease” Gordon Research Conference (GRC), Castelldefels, ES (June 28th -July 3rd)
January 2020: Invited speaker, Keystone on “Hypoxia: Molecules, Mechanisms and Disease”, Keystone, Colorado, US (January 19th – 24th)
October 2019: Invited Speaker, ISCaM, “Metabolism in cancer”, Braga, PT (October, 17th -19th)
September 2019: Invited Speaker, ESMO Annual Conference, Barcelona, ES (September 27th – October 1st)
May 2019: Invited Speaker, EMBO Workshop, “Neural guidance molecules in development and disease”, Baveno, IT (May 25th-28th)
May 2019: Invited speaker, *Nature* Conference on “Tumor adaptation to stress”, Weizmann Institute of Science, Rehovot, IL (May 13th-16th).
March 2019: Invited speaker and Session Chair, Keystone Symposia on “Cancer Metastasis: The Role of Metabolism, Immunity and the Microenvironment”, Firenze, IT (March 15th-20th)
November 2018: Keynote speaker, ABCD Conference: Signal Transduction in Cancer, MBC, University of Torino, IT (November, 22nd -24th)
November 2018: Invited speaker, “The German Society for Microcirculation and Vascular Biology” and “The Netherlands Vascular Biology Organizations”, Amsterdam, NL (November, 21st-23rd)
October 2018: Invited Speaker, ISCaM, Metabolic Adaptations & Targets in Cancer, Bratislava, SI (October, 17th -20th)
July 2018: Invited speaker, Mini-Symposium on Metabolism (4 international speakers), Bari University, IT (July 20th)
July 2018: Invited speaker, Beatson Conference on Tumor Microenvironment, Glasgow, UK (July, 1st-4th)
February 2018: Invited speaker, EMBO sectorial meeting on Immunology, Belem, Lisbon, PT (February, 22nd-23rd)
September 2017: Invited speaker, 25th ECDO Euroconference on apoptosis, topic on Cell death and immunity in disease, Leuven, BE (September 27th-29th)
June 2017: Invited speaker, 7th International Conference on Tumor Microenvironment and Angiogenesis, Centro Stefano Franscini, Monte Verità, Ascona, CH (June 25th-28th)
June 2017: Invited speaker, 4th International Congress of Translational Research in Human Nutrition, Clermont-Ferrand, FR (June 22nd-23th)

June 2017: Invited speaker, BACR Conference on Tumour Microenvironment: from Basic Science to Novel Therapies, Nottingham, UK (June 14th-16th)

May 2017: Invited speaker, European Society for Clinical Investigation, Genova, IT (May 16th-18th)

March 2017: Invited speaker, 4th Meeting of Translational Immunology, Palermo, IT (March 27th-29th)

October 2016: Invited speaker, International society of cancer metabolism, Brussels, BE (October 26th-28th)

October 2016: Invited speaker, 2nd symposium on tumor microenvironment, Frankfurt, DE (October 13th-14th)

September 2016: LKI Symposium on Tumor immunology and Immunotherapy, Leuven, BE (September 12th-14th)

May 2016: Invited speaker, EU Life meeting, Vienna, AT (May 12th -13th)

April 2016: Keynote speaker, Meeting for hematology and oncology, University of Bonn, DE (April 15th-17th)

January 2016: Invited speaker, Symposium on Angiogenesis and Cancer, IDIBELL, Barcelona, ES (January 22nd)

January 2016: Invited speaker, AACR Special Conference on The Function of Tumor Microenvironment in Cancer Progression, San Diego, CA, USA (January 7th-10th)

October 2015: Invited speaker and discussion leader, International Symposium on Metastatic CRC, Heidelberg, DE (October 29th-30th)

September 2015: Invited speaker, DKFZ-ZMBH Alliance meeting, Heidelberg, DE (September 27th-30th)

September 2015: Invited speaker, Fondazione IBSA, Immune Symposium, Lugano, CH (September 26th)

September 2015: Invited speaker and discussion leader, VIB international conference on Metabolism, Leuven, BE (September 8th-10th)

July 2015: Keynote speaker, SIBBM Conference "From Genomes to Functions", Torino, IT (July 1st-3rd)

May 2015: Invited speaker, 12th meeting of the French Neuroscience Society, Montpellier, FR (May 19th-22nd)

May 2015: Invited speaker, 6th Conference on Tumor Microenvironment, Monte Verità, CH (May 17th-20th)

May 2015: Invited speaker, Keystone Symposium on Hypoxia, Dublin, IE (May 12th-17th)

May 2015: Invited speaker, ConsEPOC International Meeting, Madrid, ES (May 4th)

April 2015: Co-organizer of the parallel session on tumor microenvironment and discussion leader, AACR Annual Meeting, Philadelphia, PA, USA (April 18th-22nd)

March 2015: Invited speaker, AACR Special Conference on Angiogenesis, Orlando, USA (March 5th-8th)

October 2014: Invited speaker, TIMCC Symposium on Tumor Microenvironment, Bonn, DE (October 22nd)

October 2014: Invited speaker, ETH Symposium on Angiogenesis and Inflammation, Zurich, CH (October 8th)

September 2014: Invited speaker, Biology & Treatment of Metastatic Cancer, El Jadida, MA (September 23rd-26th)

April 2014: Keynote speaker, French Angiogenesis Society Meeting, Chamonix, FR (April 2nd-4th)

March 2014: Invited speaker and discussion leader, Keystone Symposium on Angiogenesis, Whistler, British Columbia, CA (March 16th-21st)

February 2014: Invited speaker, AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment, San Diego, CA, USA (February 26th-March 1st)

November 2013: Invited speaker, Symposium KFO 210, Marburg, DE (November, 11th-12th)

October 2013: Invited speaker, Louis-Jeantet Symposium, Geneve, CH (October 23rd)

September 2013: Invited speaker, ESC Conference, Amsterdam, NL (August 31st-September 4th)

August 2013: Invited speaker, Gordon Conference (GRC), Newport, Rhode Island, USA (August 4th-9th)

July 2013: Invited speaker, Beatson Conference on Tumor Stroma, Glasgow, UK (June 7th-10th)

June 2013: CBCS International Summer School on Cardiovascular Sciences, Nice, FR (June 16th-20th)

June 2013: Invited speaker and discussion leader, 5th International Conference on Tumor Microenvironment and Angiogenesis, Monte Verità, Ascona, CH (June 2nd-5th)

October 2012: Invited speaker and discussion leader, FEBS meeting on Angiogenesis, Capri, IT (October 14th-17th)

September 2012: Invited speaker, Conference Italian Society of Biochem. Mol. Biol., Chieti, IT (September 26th-29th)

September 2012: Invited speaker, Annual Meeting of the European Macrophage and Dendritic Cell Society, Debrecen, HU (September 1st-3rd)

July 2012: Invited speaker, CELL Symposium on Angiogenesis, Metabolism, Cancer, Leuven, BE (July 6th-8th)

April 2012: Invited speaker, Hypoxianet 2012, Nantes, FR (April 4th)

January 2012: Invited speaker, IV International J Folkman Conference, Rome, IT (January 13th-14th)

August 2011: Invited speaker, Gordon Conference (GRC), Newport, Rhode Island, USA (August 21st-26th)

August 2011: Invited speaker and discussion leader, "Endothelial Heterogeneity in Disease" Gordon-Kenan Research Seminar (GRS), Salve Regina University, Newport, Rhode Island, USA (August 20th-21st)

June 2011: Invited speaker, CBCS Summer School on Cardiovascular Sciences Nice, FR (June 12th-16th)

October 2010: Invited speaker, HypoxiaNet 2010, UCD, Dublin, IE (October 7th-8th)

March 2010: Invited speaker, European Physiological Society Symposium, UCD, Dublin, IE (March 22nd)

March 2010: Invited speaker, AICR Annual Meeting, Galway, IE (March 3rd-6th)

May 2008: Invited speaker, 8th ESH conference on angiogenesis, Paris, FR (May 9th-12th)

February 2008: Invited speaker, 'International Symposium: Advances in Translational Research of Cardiovascular Diseases', Madrid, ES (February 14th-15th)

May 2005: Invited speaker, VI Conference of Molecular Oncology, Positano, IT

PERSONAL RESEARCH GRANTS

NATIONAL GRANTS

- January 2019:** 4-year research grant (€ 400 000) from FWO for the project G0A7419N: ‘Harnessing the pyrimidine salvaging pathway to foster anti-tumor immunity and sensitize tumors to immune checkpoint blockade’.
- January 2019:** 4-year research grant (€ 509 500) from FWO for the project G0A8219: ‘Exploring the role of PlexinA4 in cytotoxic T cells: insights for anti-tumor immune response & cancer immunotherapy’.
- January 2018:** 4-year research grant from FWO-SBO project (ZL3C3602) with a primary economic finality aimed at the transfer to existing companies; total € 1 999 749 of which € 400 583 for my laboratory; project title: Validation and druggability development of macrophage-specific targets in the tumor microenvironment (MATATUM).
- January 2017:** 4-year research grant (€ 515 000) from FWO for the project G0D1617N: ‘Exploring the role of TRAIL pathway in the tumor stroma: implications for cancer progression and drug resistance’.
- January 2017:** 4-year research grant (€ 305 116) from FWO for the project G0D1717N: ‘Metabolism following function or function following metabolism: a study of AMPK in tumor-associated macrophages’
- January 2016:** 30-month research grant (€ 229 000) from the Flemish Association against Cancer (VLK) for the project 419.052.173: ‘PHD1 as potential candidate for drug resistance in colorectal cancer’.
- January 2015:** 4-year research grant (€ 200 000) from the Belgian Association against Cancer for the project 2014-186: ‘A monocyte signature for monitoring disease relapse and response to chemotherapy in colorectal cancer patients’.
- January 2015:** 4-year research grant (€ 354 600) from the Belgian Association against Cancer for the project 2014-197: ‘Exploring the metabolic pathways driving tumor-associated macrophage polarization and their influence on tumor progression’.
- January 2015:** 4-year research grant (€ 292 000) from FWO for the project G066515N: ‘Exploring the metabolic pathways driving tumor-associated macrophage polarization and their influence on tumor progression’.
- January 2015:** 4-year research grant (€ 400 000) from FWO for the project G087615N: ‘Podoplanin: the missing link between breast cancer and lymphatic?’.
- January 2015:** Credit (€ 30 000) from FWO for the project 1501215N: ‘Mir-210 at the crossroad of M2 and M1 macrophage polarization: relevance for sepsis and cancer’.
- November 2014:** André Vander Stricht-Emile Carpentier Prize (€ 40 000).
- October 2014:** 8-year Methusalem grant from the Flemish government with the role of co-promoter (€ 75 000 per year)
- September 2014:** 4-year research grant (€ 450 000) from the Vlaamse Liga tegen Kanker for the project: ‘A monocyte signature for monitoring disease relapse in colorectal cancer patients’.
- January 2013:** 4-year research grant (€ 200 000) from FWO for the project G083613N: ‘Inhibiting FIH as a potential anti-angiogenic treatment’.
- January 2012:** 4-year research grant (€ 200 000) from FWO for the project G068612N: ‘Unraveling new molecular pathways in the oxygen sensing machinery’.
- January 2011:** 4-year research grant (€ 200 000) from FWO for the project G079311N10: ‘Peripheral blood monocytes as predictive biomarkers in colorectal cancer’.
- January 2011:** Credit (€ 10 000) from FWO for the project 1505611N00: ‘Unraveling new molecular pathways in the oxygen sensing machinery’.
- December 2010:** 4-year research grant (€ 140 000) from the Belgian Association against Cancer for the project 2010-198: ‘Peripheral blood monocytes as predictive biomarkers in colorectal cancer’.
- December 2010:** 2-year research grant (€ 140 000) from the Belgian Association against Cancer for the project 2010-169: ‘Unraveling new molecular pathways in the oxygen sensing machinery’.
- January 2010:** 4-year research grant (€ 320 000) from FWO for the project G.0726.10N: ‘Endothelial phalanx cells in therapeutic angiogenesis’.
- January 2010:** 4-year research grant (€ 82 000) from FWO for the project G071810N: ‘PHD2 oxygen sensor: novel and promising target for the optimization of chemo and radiotherapy’.
- January 2010:** Credit (€ 20 000) from FWO for the project 1520410N: ‘PHD2 oxygen sensor: novel and promising target for the optimization of chemo and radiotherapy’.

INTERNATIONAL GRANTS

- July 2020:** 3-year AFM-Telethon grant (€ 200 000) for the project: "GLUD1 as a potential target in Muscular Dystrophy". From October 2020 to September 2023.
- November 2017:** 5-year ERC Consolidator Grant (€ 2 000 000) for the project ImmunoFit (773208): ‘Harnessing tumor metabolism to overcome immunosuppression’. From June 2018 to May 2023.
- September 2017:** 3-year MSCA-ITN grant, Horizon 2020 (META-CAN) (€ 452.920 as co-PI): “Targeting the metabolism-immune system connections in Cancer”.

November 2016: 1-year ERC Proof-of-Concept (€ 150 000) for the project: “A comparative clinical study of a stool-based versus a blood-based screening test for early detection of CRC.”

May 2016: 3-year ERANET grant (€ 300 000 per participant) for the project OxyUC: “The impact of hypoxia on inflammation and tumorigenesis in Ulcerative Colitis.” Consortium with Prof. Cormac Taylor (UCD, Dublin, Ireland), Dr. Martin Shneider (University Hospital Heidelberg, Germany), Prof. Jochen Prehn (Royal College of Surgeons, Dublin, Ireland).

June 2013: 3-year research grant (€ 237 000) from the Association for International Cancer Research (AICR) for the project: ‘Podoplanin: the missing link between macrophages and lymphatic metastasis in breast cancer?’.

November 2012: 5-year ERC Starting Grant - Starter Category (€ 1 500 000) for the project OxyMO: ‘Oxygen sensing in macrophages: implications for cancer and ischemia’. From December 2012 to November 2017.

July 2012: Credit (€ 25 000) from the European Society of Cardiology for the project: ‘Regulation of post-ischemic angiogenesis and reperfusion injury by PHD2 and WNT/beta catenin pathways’.

INDUSTRIAL FUNDING AND TECH TRANSFER

July 2019: Funds from Droia (€ 540 868) in favor of Montis Biosciences, to evaluate macrophages and endothelial cells interactions in the immunosuppressive tumor environment

April 2018: Seed capital (€ 150 000) from V-BIO Ventures, 1 year grant for grounding foundation of a new spin-off.

January 2018: VLAIO research grant with CoBioRes, external service fee up to 200 000 €.

January 2018: VLAIO research grant (total € 1 798 992 of which € 541 358 for my laboratory) with J&J Belgium, Janssen Pharmaceutica, grant number HBC.2016.0883: "Targeting immunosuppressive mechanisms in cancer". From February 2018 to February 2020.

June 2017: VLAIO research grant (total € 1 122 754 of which € 168 583 for my laboratory) with Octimet, grant number HBC. 201.03657: "Combination Therapies for treatment of Resistant Tumours". From 1/06/2017 to 31/05/2019.

January 2017: Funds from DNA Lytics (€ 250 000) for the development of the Monomark test (Colonokit™).

December 2016: Funds from Merus (€ 440 000) to evaluate the in vivo effect of MET and EGFR bivalent antibodies.

November 2016: Funds from Octimet (€ 100 000) for the preclinical validation of OMO-1 (MET and OCT-2 inhibitor).

January 2016: 24-month grant (€ 12 500) from AstraZeneca Foundation (EXJ-MMWDVC-O3200).

August 2015: Funds from Droia (€ 84 000) for the pre-clinical evaluation of ITPP on tumor oxygenation and cancer progression in breast cancer mouse models.

June 2015: Funds from Merus (€ 107 000) to evaluate the in vitro effect of MET and EGFR bivalent antibodies.

May 2014: Funds from CoBioRes nv (€ 37 500) to evaluate the PhAc-ALGP-technology in breast cancer

January 2014: Funds from Boehringer Ingelheim (€ 120 000) for a biomarker analysis on plasma samples from CRC patients in relation to antiangiogenic treatments (Folfox + Avastin versus Folfox + Nintedanib; phase I/II study).

August 2013- May 2017: FFMI extensions (€ 300 000) for the development of the Monomark signature.

January 2011: Unique selected 3-year research grant (€ 345 000) from the Foundation Fournier-Majoie for the Innovation (FFMI) for the project: ‘Peripheral blood monocytes as predictive biomarkers in colorectal cancer’.

PATENTS AND SCIENCE TRANSLATION

- "PHD2 inhibition for blood vessel normalization, and uses thereof"; Massimiliano Mazzone and Peter Carmeliet; filing date 20 January 2010; published as WO 2010/084134.
- “Induction/monitoring of arteriogenesis using SDF1 and PDGFB or inhibition of PHD2”; Massimiliano Mazzone and Peter Carmeliet; filing date: March 30th 2011; published as WO2011/121036.
- “Monocyte biomarkers for cancer detection”; Massimiliano Mazzone; filing date January 28th 2013; published as WO2013/110817.
- “Modulating transendothelial migration and recruitment of granulocytes by modulating c-Met pathway”; Massimiliano Mazzone and Veronica Finisguerra; filing date August 31th 2012 (US 61/695,952).
- "PP2A subunits in DNA repair and implications for cancer"; Anna Sablina, Massimiliano Mazzone and Giusy Di Conza; filing date February 18th 2013; published as WO2013/121042.
- “Means and methods to treat inflammatory diseases”; Massimiliano Mazzone and Anne-Theres Henze; filing date October 4th 2016 (EP 16192213.3).
- “Glutamine dehydrogenase inhibitors for use in muscle regeneration”; Massimiliano Mazzone and Min Shang; filing date: June 9th 2017 and February 12th 2018 (EP 17175210.8; EP 17175210.8).
- “Glutamine synthetase inhibitors in cancer” Massimiliano Mazzone, Alessandra Castegna, Erika Palmieri, and Alessio Menga; filing date: July 20th 2017 (GB 1711709.4).
- “Podoplanin-positive macrophages” Massimiliano Mazzone and Pawel Bieniasz-Krzywiec; filing date: October 26th 2017 (EP 17198684.7).

- “CD8⁺ T cells lacking plexins and their application in cancer treatment by targeting Plexins in the immune compartment”; Massimiliano Mazzone, Ana Oliveira and Ward Celus; filing date: May 28th 2019 (EP 19176939.7).
- “Cancer treatment by targeting Plexins in the immune compartment”; Massimiliano Mazzone, Ana Oliveira and Ward Celus; filing date: May 28th 2019 (EP 19176939.7).
- “PLXA4 – Circulating biomarker for anti-tumor therapy”, Massimiliano Mazzone, Ana Oliveira, Ward Celus; filing date: September 24th 2020 (EP 20198184.2)
- “Combination of P2RY6 inhibitors and immune checkpoint inhibitors”, Massimiliano Mazzone; filing date: September 24th 2020 (GB 2015082.7).
- A novel activity of Tacrolimus in preventing muscle atrophy and cancer cachexia”, Paolo Porporato, Erica Mina, Valentina Rausch, Massimiliano Mazzone; filed by the University of Torino on October 13th 2020.
- Outlicense of an anti-phospho-PHD2 S125 (Di Conza et al., Cell Reports, 2017) to Merck Millipore, # MABC1612.
- Outlicense of the Monomark signature (WO2013/110817 and Hamm et al., Gut, 2015) to DNA Lytics (Louvain-la-Neuve, Belgium) as ColonokitTM.
- Generation of anti-Neuropilin-1 single domain antibodies and Fabs in collaboration with VIB Drug Discovery and Fair Journey Biologics (Porto, Portugal).
- Screening and validation of Glutamine Synthase inhibitors in collaboration with the Korea Research Institute of Chemical Technology (KRICT).

SPINOFF BIOTECH COMPANIES

- Scientific Founder of the oncology company **Oncurious** (September 1st, 2017)
- Seed capital for the foundation of a **second spin-off, ImmunoFit**, in the field of immune cell adaptation to the tumor microenvironment (May 1st, 2019)
- Scientific Founder with **Droia** of **Montis Biosciences**, working on tumor-associated macrophage and endothelial cell interactions (July 19th, 2019)

SCIENTIFIC SERVICE

- Editorial Board Member of: *Journal of Molecular Medicine & Therapeutics*; *Cancer Research*; *Journal of Tumor; Molecular & Cellular Oncology*; *Cytokines and Soluble Mediators in Immunity*; *Immunometabolism Journal*; *Life*.
- Guest Editor of *Molecular Aspects of Medicine* on the special issue: “Angiogenesis and Lymphangiogenesis”
- Guest Editor of *Immunometabolism* on the special issue: “Immunometabolism and Inflammation”
- Reviewer for the following journals (~40/year): Clin Cancer Res, Cancer Res, Nature, Nat Genet, Nat Biotechnol, Nat Cell Biol, Nat Commun, Nat Rev Canc, Science, Sci Immunol, Science Translational Medicine, Cell Metab, Cell Rep, Mol Cell, J Clin Invest, J Exp Med, EMBO J, EMBO Mol Med, Blood, PNAS, Plos Biol, Faseb J, Scientific Reports, Oncogene, Circulation, Cancer Immunology Research, ...
- Reviewer for the following granting agencies: FWO, IWT (BE), MIUR (IT), DFG (DE), Raine Medical Research Foundation (AU), CRUK, Wellcome Trust, AICR, MRC (UK), ISF (IL), AACR (USA), Czech Science Foundation (CZ), SNF, Swiss Cancer League (CH); NWO, KWF (NL); FCT (PT); ERC (EU).
- Part of the advisory board of: Sanofi-Aventis Zeltrap program; Metaptys NV; CoBioRes; OctiMet; DeuterOncology
- AACR and EACR active member
- Member of the Executive Board of the Leuven Cancer Center (LKI)
- Cancer UK advisory panel member
- Consultant for the Italian Ministry for University and Research
- Member of the boards of the PhD program in Cancer and of the PhD program in Cardiovascular Medicine, KU Leuven
- Internal Advisory Panel member, Department of Oncology, KU Leuven
- User Committee Member, VIB-KU Leuven FACS Core
- Member of the scientific board of Stichting tegen kanker – Belgian Association against Cancer
- Mentoring committee, Tenure Track Program, Ludwig Cancer Center, Lausanne University, CH
- Member of the European Academy for Tumor Immunology

ORGANIZATION OF INTERNATIONAL CONFERENCES

- Co-Organizer VIB Conference on ImmunoOncology (2022) in Leuven (BE)
- Co-Organizer VIB Training on Organoids (2021) in Leuven (BE)
- Organizer METACAN Training Conference (MSCA-ITN, Horizon 2020) on “Mouse models, organoids and large data analysis”, Leuven, Belgium (September 23rd-27th, 2019)

- Organizer VIB Conference on Metabolism in Cancer and Stromal Cells (November 26th-27th, 2018) in Leuven (BE)
- Member of the Scientific Committee, 4th International Congress of Translational Research in Human Nutrition, topic on nutrition and cancer; Clermont-Ferrand, France (June 22nd-23rd, 2017)
- Organizer VIB Symposium on Cell Metabolism (September 6th, 2016) in Leuven (BE)
- Co-organizer parallel session on tumor microenvironment, AACR, Philadelphia, PA (April 18th-22nd, 2015)

RESEARCH ACTIVITY

- Developed lentiviral vector-based antagonists and antibodies against HGF/MET signaling in the context of cancer
- Identified the role of MET in neutrophils during inflammation and cancer
- Identified possible mechanisms of resistance to chemotherapy and anti-angiogenic drugs
- Studied PHD2 in endothelial cells and macrophages using cancer and ischemia mouse models
- Characterized post-translational modifications of PHD2 and the PHD2 interactome
- Studied the effect of macrophage polarization, metabolism and localization on tumor immunity, angiogenesis, metastasis and response to chemotherapy
- Studied new immunotherapeutic strategies and combination treatments to foster anti-cancer immunity
- Developed a monocyte-based test for colorectal cancer diagnosis, licensed to DNA Lytics (Colonokit™)

MAJOR SCIENTIFIC COLLABORATIONS

Angiogenesis and cancer invasion: L. Claesson-Welsh, E. Dejana (SE), K. Alitalo (FI), H. Gerhardt (DE), M. Simons (US), D. Hanahan (CH), D. Taverna, L. Tamagnone, G. Serini (IT). **Clinics:** H. Prenen, S. Tejpar, A. D'Hoore, A. Smeets, G. Floris, X. Sagaert, M.F. Bosisio, A. Hendlisz (BE), F. Loupakis, G. Gasparini (IT), T. Tueting, M. Schneider, T. Schmidt, S. Schölch, J. Weitz (DE). **Hypoxia:** M. Ivan (US), C. Taylor (IE), P.J. Ratcliffe, P. Maxwell, M. Whyte (UK). **Immunometabolism:** S. Kaech (US), H. Ping-Chih, P. Romero (CH). **Immunity:** M. De Palma, G. Coukos (CH), G. Bergers, J. Van Ginderachter, A. Liston, B. Vanden Eynde, P. Coulie (BE), A. Mantovani (IT), M. Hoelzel (DE), C. Lewis (UK), Z. Granot (IL). **Metabolism:** P. Carmeliet, S. Fendt, B. Ghesquière, J. Swinnen, Bommer (BE), C. Muñoz-Pinedo (ES), S. Zanivan, C. Frezza (UK), A. Castegna (IT), J. Aragones-Lopez (ES). **Bioinformatics:** D. Lambrechts, S. Aerts, C. Marine (BE), B. Evers (NL).

SCIENTIFIC PRODUCTIVITY

- 126 articles in peer-reviewed journals, of which 95 research papers (5 as first author and **19 as senior author, 20 as corresponding author**), 19 reviews (3 as first author and 9 as last author, of which 11 as corresponding author) and 12 editorials/commentaries (3 as first author of which one as corresponding author, 7 as last author plus 1 as only author of which all 8 as corresponding author); 2 book chapters; 14 patents
- Cumulative impact factor: 1710.56
- Cumulative impact factor of first / senior / corresponding author research papers: 469.07
- Average impact factor of first or senior corresponding author research papers: 15.60
- Cumulative citations index (ISI web of science): 9631 (no self-citations included)
- Cumulative citation index of first / senior / corresponding author research papers (ISI web of science): 2496 (no self-citations included)
- H index: 46

LIST OF PUBLICATIONS

*Equal Contributors; #Corresponding Author; IF Impact Factor publication year; C Citations (no self-citations)

PUBLISHED

1. Flerin N, Cappellesso F, Pretto S, and **Mazzone M[#]**. Metabolic traits ruling the specificity of the immune response in different cancer types. *Current Opinion in Biotechnology*, in press. IF=8.30
2. Castegna A, **Mazzone M[#]**. Metabolism tailors macrophage functions: one size does not fit all. *Immunometabolism*. 2020;2(4):e200033 (2020). IF=3.64
3. Rodriguez, H., Prados-Rosales, R., Lavin, J.L., **Mazzone, M.**, Anguita, J. Macrophage Metabolism and Immune Responses (*Editorial*). *Front Immunol*, 11:1078 (2020). IF=5.09
4. Menga A, Serra M, Todisco S, Riera Domingo C, Ammarah U, Ehling M, Palmieri E, Di Noia M-A, Gissi R, Favia M, Pierri CL, Porporato P, Castegna A, **Mazzone M[#]**. Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages. *EMBO Mol Med*, Epub ahead of print. IF=8;82

5. Shang M, Cappellesso F, Amorim R, Serneels J, Virga F, Eelen G, Carobbio S, Rincon MY, Maechler P, De Bock K, Ho PC, Sandri M, Ghesquière B, Carmeliet P, Di Matteo M, Berardi E, and **Mazzone M[#]**. (2020). Macrophage-derived glutamine boosts satellite cells and muscle regeneration. *Nature*, doi: 10.1038/s41586-020-2857-9. *Epub ahead of print*. IF=42.78
6. Stakenborg M, Verstockt B, Meroni E, Goverse G, De Simone V, Verstockt S, Di Matteo M, Czarnewski P, Villablanca EJ, Ferrante M, Boeckxstaens GE, **Mazzone M**, Vermeire S, Matteoli G. (2020). Neutrophilic HGF-MET signaling exacerbates intestinal inflammation. *Journal of Crohn's and Colitis*, doi.org/10.1093/ecco-jcc/jjaa121. IF=8.66
7. D'Anna F, Van Dyck L, Xiong J, Zhao H, Berrens RV, De Smedt J, Bieniasz-Krzywiec P, Chandra V, Schoonjans L, Matthews J, Minnoye L, Qian J, Amorim R, Khorasanizadeh S, Zhao L, Yu Q, De Borre M, Savvides SN, Simon C, Carmeliet P, Reik W, Rastinejad F, **Mazzone M**, Thienpont B, Lambrechts D. (2020). DNA Methylation Repels Binding of HIF transcription factors to maintain tumour immunotolerance. *Genome Biology*, 27(1):182. IF=10.81
8. Nasrollahzadeh E, Razi S, Keshavarz-Fathi M, **Mazzone M**, Rezaei N. (2020). Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. *Cancer Immunol Immunother*, doi: 10.1007/s00262-020-02616-6. IF=5.44; C=2
9. Ehling M, Celus W, Martín-Pérez R, Alba-Rovira R, Willox S, Ponti D, Cinta M, Jones E, Di Conza G, and **Mazzone M[#]**. (2020). B55a/PP2A limits endothelial cell apoptosis during vascular remodeling: a complementary approach to kill pathological vessels? *Circulation Research*, doi:10.1161/CIRCRESAHA.119.316071. IF=15.9
10. Serra M, Columbano A, Ammarah U, **Mazzone M[#]**, and Alessio Menga. Understanding metal dynamics between cancer cells and macrophages: competition or synergism? *Front. Oncol.* Doi: 10.3389/fonc.2020.00646 (2020). IF= 4.85
11. Bieniasz-Krzywiec P, **Mazzone, M**. PoEMS edit breast cancer outcome. *Aging*, 12 (5):4045-4047. (Editorial) (2020). IF=4.83
12. Goveia, J., Rohlenova, K., Taverna, F., Treps, L., Conradi, L-C., Pircher, A., Geldhof, V., de Rooij, L., Kalucka, J., Sokol, L., Garcia-Caballero, M., Zheng, Y., Qian, J., Teuwen, L-A., Khan, S., Boeckx, B., Wauters, E., Decaluwé, H., De Leyn, P., Vansteenkiste, J., Weynand, B., Sagaert, X., Verbeken, E., Wolthuis, A., Topal, B., Everaert, W., Bohnenberger, H., Emmert, A., Panovska, D., De Smet, F., Staal, F., McLaughlin, RJ, Impens, F., Lagani, V., Vinckier, S., **Mazzone, M.**, Schoonjans, L., Dewerchin, M., Eelen, G., Karakach, TK, Yang, H., Wang, J; Bolund, L., Lin L., Thienpont, B., Li, X., Lambrechts, D., Luo, Y. Carmeliet, P. An integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. *Cancer Cell*, 37(1):21-36 (2020). IF=26.60; C=17
13. Flerin NC, Pinioti S, Menga A, Castegna A, **Mazzone M[#]**. (2020) Impact of immunometabolism on cancer metastasis: a focus on T cells and macrophages. *Cold Spring Harbor Laboratory Perspectives in Medicine*, review paper and book chapter. Doi: 10.1101/cshperspect.a037044. IF=5.56; C=2
14. Tisch, N., Freire-Valls, A., Yerbes, R., Paredes, I., La Porta, S., Wang, X., Martín-Pérez, R., Castro, L., Wei-Lynn Wong, W., Coultas, L., Strilic, B., Gröne, H.J., Hielscher, T., Mogler, C., Adams, R., Heiduschka, P., Claesson-Welsh, L., **Mazzone, M.**, López-Rivas, A., Schmidt, T., Augustin, H.G., Ruiz de Almodovar, C. Caspase-8 modulates physiological and pathological angiogenesis during retina development. *J Clin Invest*, 129(12):5092-5107 (2019). IF=11.86; C=2
15. Bieniasz-Krzywiec P, Martín-Pérez R, Ehling M, Kroes R, Aldeni C, García-Caballero M, Prenen H, Noel A, Smeets A, Floris G, Van Ginderachter JA, and **Mazzone M[#]**. Podoplanin-expressing macrophages are required for lymphangiogenesis and lymphatic metastasis in breast cancer. *Cell Metabolism*, 30 (5):917-947 (2019). IF=21.57; C=15
16. Riera Domingo C, Costa Granja S, Audige A, Baltazar F, Stockmann C, Ho PC, and **Mazzone M[#]**. Immunity, Hypoxia, and Metabolism - the ménage à trois of cancer: implications for immunotherapy. *Physiological Reviews*, 100(1):1-102 (2019). IF=25.59; C=8
17. Bacci M, Lorito N, Ippolito L, Ramazzotti M, Luti S, Romagnoli S, Parri M, Bianchini F, Cappellesso F, Virga F, Gao Q, Simões BM, Marangoni E, Martin LA, Comito G, Ferracin M, Giannoni E, **Mazzone M**, Chiarugi P, Morandi A. Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer. *Cell Reports.*, 28:104-118 (2019). IF=8.11; C=9
18. Virga, F, Ehling, M and **Mazzone, M[#]**. Blood Vessel Proximity Shapes Cancer Cell Metabolism. *Cell Metabolism*, 30(1):16-18 (2019). IF=21.57; C=1

19. García-Caballero M, Zecchin A, Souffreau J, Khanh Truong A, Teuwen L-A, Vermaelen W, Martín-Pérez R, de Zeeuw P, Bouché A, Vinckier S, Cornelissen I, Eelen G, Ghesquière B, **Mazzone M**, Dewerchin M, and Carmeliet P. Role and therapeutic potential of dietary ketone bodies for lymph vessel growth. *Nature Metabolism*, 1:666-675 (2019). C=11
20. Tacconi C, Ungaro F, Correale C, Arena V, Massimino F, Detmar M, Spinelli A, **Mazzone M**, Oliveira A, Rubbino F, Garlatti V, Spano S, Lugli E, Colombo FS, Malesci A, Peyrin-Biroulet L, Vetrano S, Danese S, D'Alessio S. Activation of the VEGF/VEGFR3 pathway induces tumor immune escape in colorectal cancer. *Cancer Res*. 79(16):4196-4210 (2019). IF=9.73 ; C=11
21. Harris AJ, Mirchandani AS, Lynch RW, Murphy F, Delaney L, Small D, Coelho P, Watts ER, Sadiku P, Griffith D, Dickinson RS, Clark E, Willson JA, Morrison T, **Mazzone M**, Carmeliet P, Ghesquiere B, O'Kane C, McAuley D, Jenkins SJ, Whyte MKB, Walmsley SR. IL4R α Signaling Abrogates Hypoxic Neutrophil Survival and Limits Acute Lung Injury Responses In Vivo. *Am J Respir Crit Care Med*. 200(2):235-246 (2019). IF=17.45; C=9
22. **Mazzone M**[#], and Bergers G. Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. *Annu Rev Physiol*, 81, 535-560. doi:10.1146/annurev-physiol-020518-114721. (2019). IF=19.56; C=7.
23. Prenen H, and **Mazzone M**[#]. Tumor-associated macrophages: a short compendium. *Cellular and Molecular Life Sciences*, 76(8):1447-1457 (2019). IF=6.50; C=23
24. Kugeratski F, Atkinson S, Neilson J, Lilla S, Knight J, Serneels J, Juin A, Neilson MP, Ismail S, Bryant DM, Markert EK, Machesky LM, **Mazzone M**, Sansom OJ, and Zanivan S. Hypoxic cancer-associated fibroblasts up-regulate NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. *Science Signaling*, 12(567) article number eaan8247 (2019). IF=6.47; C=10
25. Travelli C, Consonni F, Sangaletti S, Storto M, Morlacchi S, Grolla T, Galli U, Tron G, Portararo P, Rimassa L, Pressiani T, **Mazzone M**, Ugel S, Bronte V, Tripodo C, Colombo M, Genazzani A, and Sica A. Nicotinamide Phosphoribosyltransferase (NAMPT) acts as a metabolic gate of suppressor myeloid cells mobilization. *Cancer Res*, 79 (8):1938-1951 (2019). IF=9.73; C=13
26. Smeets D, Miller I, O'Connor D, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken N, Cremolini C, Prenen H, **Mazzone M**, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy B, McNamara D, Kay E, Verheul H, Neerinx M, Gallagher W, Murphy V, Prehn J, Koopman M, Punt C, Loupakis F, Ebert M, Ylstra B, Byrne A., and Lambrechts D. Copy number load predicts outcome of metastatic colorectal cancer patients receiving Bevacizumab combination therapy. *Nature Communications*, 9(1):4112 (2018). IF=11.88; C=24.
27. Missiaen R, **Mazzone M**, and Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. *Seminars in Cancer Biology*, 52(Pt 2):107-116 (2018). IF=9.66; C=17.
28. Grover SP, Saha P, Humphries J, Lyons OT, Patel AS, Serneels J, Modarai B, **Mazzone M**, Smith A. Inhibition of prolyl hydroxylase domain proteins selectively enhances venous thrombus neovascularisation. *Thromb Res*, 169:105-112 (2018). IF=3.27
29. Caljon G, Stijlemans B, De Trez C, **Mazzone M**, Tacchini-Cottier F, Malissen M, Van Ginderachter JA, Magez S, De Baetselier P, and Van Den Abbeele J. Neutrophils enhance early Trypanosoma brucei infection onset. *Scientific Reports*, 8(1):11203 (2018). IF=4.01; C=7.
30. Kalucka J*, Bierhansl L*, Conchinha N*, Missiaen R*, Elia I, Brüning U, Scheinok S, Treps L, Cantelmo AR, Dubois C, de Zeeuw P, Goveia J, Zecchin A, Taverna F, Morales-Rodriguez F, Brajic A, Conradi LC, Schoors S, Harjes U, Vriens K, Cubbon R, Thienpont B, Cruys B, Wong B, Ghesquière B, Dewerchin M, De Bock K, Sagaert X, Jessberger S, Jones E, Gallez B, Lambrechts D, **Mazzone M**, Eelen G, Li X, Fendt S, and Carmeliet P. Quiescent endothelial cells upregulate fatty acid β -oxidation for vasculoprotection via redox homeostasis. *Cell Metabolism*, S1550-4131(18):30459-30465 (2018). IF=22.42; C=36.
31. Brüning U*, Morales F*, Kalucka J, Schoonjans L, Goveia J, Taverna F, Queiroz K, Chen R, Dubois C, Cantelmo AR, Lorocho S, Timmerman E, Bloch K, Conradi LC, Treps L, Staes A, Schoonjans L, Gevaert K, Tee A, Dewerchin M, Semenkovich C, Impens F, Schilling B, Verdin E, Swinnen J, Meier J, Sickmann A, Ghesquière B, Li X, **Mazzone M**, and Carmeliet P. Impairment of Angiogenesis by fatty acid synthase inhibition involves mTOR malonylation. *Cell Metabolism*, S1550-4131(18):30462-304675. IF=22.42; C=36.
32. **Mazzone M**[#], Finisguerra V, and Prenen H. Is there merit for MET-targeted therapies in Gastro-Oesophageal cancer? *JAMA Oncology*, 4(1):131-132 (2018). IF=22.42.

33. Celus W, Di Conza G, Oliveira AI, Ehling M, Costa BM, Wenes M, and **Mazzone M[#](Lead Contact)**. Loss of Caveolin-1 in metastasis-associated macrophages drives metastatic growth through increased angiogenesis. *Cell Reports*, 21(10):2842-2854 (2017). IF=8.0; C=26.
34. **Mazzone M[#]**, Menga A, and Castegna A. Metabolism and TAM functions: it takes two to tango. *FEBS J*, 284(6):967-984 (2017), *Invited Review, Special Issue on TAMs, Guest Editor: Alberto Mantovani*. IF=4.5; C=24
35. Martín-Pérez R, Yerbes R, Mora-Molina R, Cano-González A, Arribas J, **Mazzone M**, López-Rivas A, and Palacios C. Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. *Oncotarget*, 8(55):93688-93703 (2017). IF=5.2, C=1.
36. Mathivet T, Bouleti C, Verschuere T, Stanchi F, Van Woensel F, Phng LK, Dejaegher J, Balcer M, **Mazzone M**, De Vleeschouwer S, and Gerhardt H. Dynamic stroma reorganization drives blood vessel abnormalization during glioma progression. *EMBO Mol Med*, 9(12):1629-1645 (2017). IF= 10.3; C=16.
37. Wang X, Valls AF, Schermann G, Shen Y, Moya I.M, Castro L, Urban S, Solecki GM, Winkler F, Riedemann L, Jain RK, **Mazzone M**, Schmidt T, Fischer T, Halder G, and Ruiz de Almodóvar C. YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis. *Dev Cell*, 42(5):462-478 (2017). IF=9.6; C=86.
38. Sadiku P, Willson J, Dickinson R, Murphy F, Harris A, Mirchandani A, Ryan E, Watts E, Lewis A, Sammut D, Thompson R.A.A, Marriott H, Dockrell D, Taylor C, Schneider M, Maxwell P, **Mazzone M**, Moral V, Pugh C, Ratcliffe P, Schoofield C, Gesquière B, Carmeliet P, Whyte M, and Walmsley S. Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses. *The Journal of Clinical Investigation* 127(9):3407-3420 (2017). IF=13.3; C=31.
39. Glodde N, Bald T, van den Boorn-Konijnenberg D, Szczepanski S, Brandes M, Eickhoff S, Sonneck M, Kastenmüller W, Janzen V, **Mazzone M**, Smyth MJ, Tüting T, and Hölzel M. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. *Immunity*, 47(4):789-802 (2017). IF=19.7 ; C=75.
40. Kiss M, Czimmerer Z, Nagy G, Bieniasz-Krzywiec P, Ehling M, Pap A, Poliska S, Boto P, Tzerpos P, Horvath A, Kolostyak Z, Daniel B, Szatmari I, **Mazzone M**, Nagy L. Retinoid X Receptor suppresses a metastasis-promoting transcriptional program in myeloid cells via a ligand-insensitive mechanism. *P Natl Acad Sci USA*, 114(40):10725-10730. (2017). IF=9.5; C=7.
41. Palmieri E, Menga A, Martín-Pérez R, Quinto A, Riera-Domingo C, De Tullio G, Lamers W, Hooper D, Ghesquière B, Guarin A, **Mazzone M^{#,*} (Lead Contact)**, and Castegna A^{#,*}. Pharmacologic or genetic targeting of glutamine synthase skews macrophages towards an M1-like phenotype and strongly inhibits tumor metastasis. *Cell Reports*, 20(7):1654-1666 (2017). IF=8.0; C=71.
42. Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, Di Conza G, Cheng WC, Chou CH, Vavakova M, Muret C, Debackere K, **Mazzone M**, Huang HD, Fendt SM, Ivanisevic J, and Ho PC. α -ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. *Nat Immunol*. 18(9):985 (2017) IF=21.8; C=176.
43. Reid SE, Kay EJ, Neilson LJ, Henze AT, Serneels J, McGhee EJ, Dhayade S, Nixon C, Mackey JB, Santi A, Swaminathan K, Athineos D, Papalazarou V, Patella F, Roman-Fernandez A, ElMaghloob Y, Hernandez-Fernaud JR, Adams RH, Ismail S, Bryant DM, Salmeron-Sanchez M, Machesky LM, Carlin LM, Blyth K, **Mazzone M**, and Zanivan S. Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. *EMBO Journal*, 36(16):2373-2389. (2017) IF=10.6; C=54.
44. Di Conza G, Trusso Cafarello S, Zheng X, Zhang Q, and **Mazzone M[#] (Lead Contact)**. PHD2 targeting overcomes breast cancer cell death upon glucose starvation in a PP2A/B55 α -mediated manner. *Cell Reports*, 18(12): 2836-2844 (2017). IF=8.0; C=13.
45. Mancini F, Teveroni E, Di Conza G, Monteleone V, Arisi I, Pellegrino M, Buttarelli M, Pieroni L, D'Onofrio M, Urbani A, Pontecorvi A, **Mazzone M**, and Moretti F. MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. *Molecular Cancer*, 16(1): 55 (2017). IF=7.8; C=5.
46. Hernandez-Fernaud JR, Ruengeler E, Casazza A, Neilson LJ, Pulleine E, Santi A, Ismail S, Lilla S, Dhayade S, MacPherson IR, McNeish I, Ennis D, Ali H, Kugeratski FG, Al Khamici H, van den Biggelaar M, van den Berghe P, Cloix C, McDonald L, Millan D, Hoyle A, Kuchnio A, Carmeliet P, Valenzuela S, Blyth K, Yin H, **Mazzone M**, Norman JC, and Zanivan S. Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. *Nature Communications*, 8: 14206 (2017). IF=12.4; C=24.
47. Menga A, Palmieri E, Cianciulli A, Infantino V, **Mazzone M**, Castegna A, and Iacobazzi V. SLC25A26 overexpression impairs CaSki cells function via mtDNA hypermethylation and rewiring of the methyl metabolism.

48. Thompson AAR, Dickinson RS, Murphy F, Thomson JP, Marriott HM, Tavares A, Willson J, Williams L, Lewis A, Mirchandani A, Dos Santos Coelho P, Doherty C, Ryan E, Watts E, Morton NM, Forbes S, Stimson RH, Hameed AG, Arnold N, Preston JA, Lawrie A, Finisguerra V, **Mazzone M**, Sadiku P, Goveia J, Taverna F, Carmeliet P, Foster SJ, Chilvers ER, Cowburn AS, Dockrell DH, Johnson RS, Meehan RR, Whyte M, and Walmsley S. Hypoxia determines survival outcomes of bacterial infection through HIF-1 α dependent reprogramming of leukocyte metabolism. *Science Immunology*, 2:8 (2017). IF=10.55; C=26.
49. Di Conza G, Cafarello ST, Lorocho S, Mennerich D, Deschoemaeker S, Di Matteo M, Ehling M, Gevaert K, Prenen H, Peiman Zahedi R, Sickmann A, Kietzmann T, and **Mazzone M[#](Lead Contact)**. The mTOR and regulate PHD2 phosphorylation and fine tune HIF1 α levels and colorectal cancer cell survival under hypoxia. *Cell Reports*, 18(7): 1699-1712 (2017). IF=8.0; C=30.
50. Verbeke L, Mannaerts I, Schierwagen R, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, **Mazzone M**, Nevens F, van Grunsven LA, Trebicka J, and Laleman W. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. *Science Reports*, 6: 33453 (2016). IF=5.3; C=71.
51. Palmieri E, Menga A, Hooper D, **Mazzone M[#]**, Castegna A. Blockade of glutamine synthetase enhances inflammatory response in microglial cells. *Antioxidants & Redox Signaling*, 26(8): 351-363 (2017). IF=6.3; C=28.
52. Wenes M, Shang M, Di Matteo M, Goveia J, Martín-Pérez R, Serneels J, Prenen H, Ghesquière B, Carmeliet P, and **Mazzone M[#]**. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. *Cell Metabolism*, 24(5): 701-715, (2016). Selected for the special issue on Cancer Metabolism. IF=18.1; C=132.
53. Laoui D, Keirsse J, Morias Y, Van Overmeire E, Elkrim Y, Lahmar Q, Scott CL, Serneels J, Hammad H, **Mazzone M**, De Baetselier P, Guillemins M, and Van Ginderachter J. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. *Nature Communications*, 7: 13720 (2016). IF=12.1; C=74.
54. Stijlemans B, Brys L, Korf H, Bieniasz-Krzywiec P, Sparkes A, Vansintjan L, Leng L, Vanbekberge N, **Mazzone M**, Magez S, Van Ginderachter J, Beschin A, Bucala R, and De Baetselier P. MIF-mediated hemodilution promotes pathogenic anemia in experimental African trypanosomiasis. *Plos Pathogens*, 12(9): e1005862 (2016). IF= 6.6; C=11.
55. Thienpont B, Steinbacher J, Zhao H, D'Anna F, Kuchnio A, Coleman M, Ghesquière B, Van Dyck L, Ploumakis A, Boeckx B, Schoonjans L, Hermans E, Amant F, Kristensen VN, Peng Koh K, **Mazzone M**, Carell T, Carmeliet P, and Lambrechts D. Tumor hypoxia causes DNA hypermethylation by reducing TET activity. *Nature*, 537(7618): 63-68 (2016). IF= 40.1; C=229.
56. Henze A-T and **Mazzone M**. The impact of hypoxia on tumor associated macrophages (TAMs). *The Journal of Clinical Investigation*, 126(10): 3672-3679 (2016). *Invited Review*. IF=12.8; C=101.
57. Marsch E, Demandt JAF, Theelen TL, Tullemans BME, Wouters K, Boon MR, van Dijk TH, Gijbels MJ, Dubois LJ, Meex SJR, **Mazzone M**, Hung G, Fisher EA, Biessen EAL, Daemen MJAP, Rensen PCN, Carmeliet P, Groen AK, and Sluimer JC. Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolemia, atherosclerosis and hyperglycemia. *European Heart Journal*, 37(39): 2993-2997 (2016). IF=19.6; C=19.
58. Ehling M and **Mazzone M[#]**. Vessel normalization in the spot-LIGHT of cancer treatment. *Trends in Mol Med*, 22(2): 85-87 (2016). IF=10.7; C=2.
59. Finisguerra V, Prenen H, and **Mazzone M[#]**. Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma. *Oncogene*, 35(42): 5457-5467 (2016). *Invited Review*. IF=7.5; C=13.
60. Hamm A, Prenen H, van Delm W, Di Matteo M, Wenes M, Delemarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, D'Hoore A, Iserentant H, Hendlisz A, and **Mazzone M[#]**. Tumor-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. *Gut*, 65(6): 990-1000 (2016). IF=16.6; C=26.
61. Prenen H, Smeets D, **Mazzone M**, Lambrechts D, Sagaert X, Sciot R, Debiec-Rychter M. Phospholipase C Gamma 1 (PLCG1) R707Q mutation is counter selected under targeted therapy in a patient with hepatic angiosarcoma. *Oncotarget*, 6(34): 36418-36425 (2015). IF=5; C=10.
62. Hasan A and **Mazzone M**. Sixty shades of oxygen - an attractive opportunity for cancer immunotherapy. *Annals of Translational Medicine*, 3(13): 187 (2015); C=2.

63. Brossa A, Grange C, Mancuso L, Annaratone L, Satolli MA, **Mazzone M**, Camussi G, and Bussolati B. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. *Oncotarget*, 6(13): 11295-11309 (2015). IF=5; C=19.
64. Kuchnio A, Bruening U, Hens J, Georgiadou M, Katrien De Bock, Rodrigo Leite-de-Oliveira, Bruyère F, Cuervo H, Brian W, Zanivan S, Sahai E, Vinckier S, Dewerschin M, **Mazzone M**, and Carmeliet P. The cancer cell oxygen sensor PHD2 promotes metastasis via activation of cancer-associated fibroblasts. *Cell Reports*, 12: 1-14 (2015). IF=7.9; C=48.
65. Deschoemaeker S, Di Conza G, Lilla S, Martín-Pérez R, Mennerich D, Boon L, Hendriks L, Maddocks O, Marx, Radhakrishnan P, Prenen H, Schneider M, Myllyharju J, Kietzmann T, Vousden K, Zanivan S, and **Mazzone M**[#]. PHD1 regulates p53-mediated colorectal cancer chemoresistance. *EMBO Mol Med*, 7(10): 1350-1365 (2015). IF=9.2; C=26.
66. Verheijden S, Beckers L, Casazza A, Butovsky O, **Mazzone M**, and Baes M. Identification of a chronic non-neurodegenerative microglia activation state in a mouse model of peroxisomal β -oxidation deficiency. *Glia*, 63(9): 1606-1620 (2015). IF=6; C=23.
67. Kiriakidis S, Henze AT, Kruszynska-Ziaja I, Skobridis K, Theodorou V, Paleolog EM, and **Mazzone M**[#]. Factor inhibiting hif-1 (fih-1) is required for human vascular endothelial cell survival. *Faseb J*, 29(7): 2814-2827 (2015). IF=5.3; C=14.
68. Gomez-Rodriguez V, Orbe J, Martinez-Aguilar E, Rodriguez JA, Fernandez-Alonso L, Serneels J, Bobadilla M, Pérez Ruiz A, Collantes M, **Mazzone M**, Paramo JA, and Roncal C. Functional MMP-10 is required for efficient tissue repair following experimental hind limb ischemia. *Faseb J*, 29(3): 960-972 (2015). IF=5.3; C=9.
69. Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson R, Wauters E, Walmsley S, Prenen H, Granot Z, Casazza A, and **Mazzone M**[#]. MET is required for the recruitment of anti-tumoural neutrophils. *Nature*, 522(7556): 349-353 (2015). IF=38.1; C=161.
70. Parkash J, Messina A, Langlet F, Cimino I, Loyens A, Mazur D, Gallet S, Balland E, Malone SA, Pralong F, Cagnoni G, Schellino R, De Marchis S, **Mazzone M**, Pasterkamp RJ, Tamagnone L, Prevot V, and Giacobini P. Semaphorin 7A regulates neuroglial plasticity in the adult hypothalamic median eminence. *Nature Communications*, 6:6385 (2015). IF=11.3; C=53.
71. Kahlert C, Fiala M, Musso G, Halama N, Keim S, **Mazzone M**, Lasitschka F, Pecqueux M, Klupp F, Schmidt T, Rahbari N, Schölch S, Pilarsky C, Ulrich A, Schneider M, Weitz J, and Koch M. Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. *Oncotarget*, 5(24): 12978-12989 (2014). IF=6.4; C=17.
72. Magrini E, Villa A, Angiolini F, Doni A, Mazzaro G, Rudini N, Maddaluno L, Komuta M, Topa B, Prenen H, Schachner M, Confalonieri S, Dejana E, Bianchi F, **Mazzone M**, and Cavallaro U. Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization. *The Journal of clinical investigation*, 124(10): 4335-4350 (2014). IF=13.2; C=30.
73. Tugues S, Orlova A, Roche F, Bhoi S, Padhan N, Noguer O, Åkerud P, Honjo S, Selvaraju RK, **Mazzone M**, Tolmachev V, and Claesson-Welsh L. Histidine-Rich Glycoprotein uptake and turnover is mediated by mononuclear phagocytes. *Plos One*, 9(9): e107483 (2014). IF=3.2; C=12.
74. Casazza A and **Mazzone M**[#]. Altering the intratumoural localization of macrophages to inhibit cancer progression. *OncoImmunology*, 3(1): e27872 (2014). IF=6.3; C=5.
75. Iovine B, Oliviero G, Garofalo M, Orefice M, Nocella F, Borbone N, Piccialli V, Centore R, **Mazzone M**, Piccialli G, and Bevilacqua M. The Anti-proliferative effect of L-carnosine correlates with a decreased expression of Hypoxia Inducible Factor 1 alpha in human colon cancer cells. *Plos One*, 9(5): e96755 (2014). IF=3.2; C=37.
76. Giacobini P, Parkash J, Campagne C, Messina A, Casoni F, Vanacker C, Langlet F, Hobo B, Cagnoni G, Gallet S, Hanchate NK, Mazur D, Taniguchi M, **Mazzone M**, Verhaagen J, Ciofi P, Bouret SG, Tamagnone L, and Prevot V. Brain endothelial cells control fertility through ovarian-steroid-dependent release of Semaphorin 3A. *Plos Biol*, 2(3): e1001808 (2014). IF=9.3; C=32.
77. Casazza A, Di Conza G, Wenes M, Finisguerra V, Deschoemaeker S, and **Mazzone M**[#]. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. *Oncogene*, 33(14): 1743-1754 (2014). *Invited Review*; IF=8.5; C=120.
78. Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter J, Tamagnone L, and **Mazzone M**[#]. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores anti-tumor immunity. *Cancer Cell*, 24(6): 695-709 (2013). *Featured*

article; IF=23.9; C=258.

79. Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, Movahedi K, Houbracken I, Schoupe E, Elkrim Y, Karroum O, Jordan B, Carmeliet P, Gysemans C, De Baetselier P, **Mazzone M**, and Van Ginderachter JA. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. *Cancer Research*, 74(1): 24-30 (2013). IF=9.3; C=200.
80. Luca R, Averna M, Vecchi M, Zalfa F, La Fata G, Bianchi F, Bianchi M, Nuciforo P, Del Nonno F, De Rubeis S, Moura R, Munck S, Parrella P, Signori E, Fazio V.M., Nardacci R, Piacentini M, Carmeliet P, **Mazzone M**, and Bagni C. The Fragile X Protein binds mRNAs involved in cancer. *EMBO Mol Med*, 5(10): 1523-1536 (2013). IF=8.2; C=59.
81. **Mazzone M**[#]. The “cord of life” serving anti-angiogenic therapy. *Blood*, 121(21): 4254-4255 (2013). *Invited Commentary*; IF=9.8
82. Bussolati B, Lauritano C, Moggio A, Collino F, **Mazzone M**, and Camussi G. Renal CD133⁺/CD73⁺ progenitors produce erythropoietin under hypoxia and prolyl hydroxylase inhibition. *J Am Soc Nephrol*, 24(8): 1234-1241 (2013). IF=9.5; C=13.
83. Hamm A, Veschini L, Takeda Y, Costa S, Delamarre E, Squadrito ML, Henze AT, Wenes M, Serneels J, Pucci F, Roncal C, Alitalo K, De Palma M, and **Mazzone M**[#]. PHD2 regulates arteriogenic macrophages through TIE2 signaling. *EMBO Mol Med*, 5(6): 843-857 (2013). IF=8.2; C=29.
84. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, Bianciotto M, Jonckx B, Badorc A, Murakami M, Lanahan A, Michielsen C, Sibrac D, Dol-Gleizes F, **Mazzone M**, Zacchigna S, Herault JP, Fischer C, Rigon P, Ruiz de Almodovar C, Claes F, Blanc I, Poesen K, Zhang J, Segura I, Gueguen G, Savi P, Bordes MF, Lambrechts D, Broussy R, Dumas A, van de Wouwer M, Laplace M, Michaux C, Shimada T, Jean I, Blacher S, Bourrie B, Noel A, Motte P, Rom E, Rakic JM, Katsuma S, Schaeffer P, Yayon A, Van Schepdael A, Carmeliet G, Wendt U, Rozensky J, Dewerchin M, Simons M, Christopoulos A, Herbert J, and Carmeliet P. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. *Cancer Cell*, 23(4): 477-488 (2013). IF=23.9; C=91.
85. Langlet F, Levin BE*, Luquet S*, **Mazzone M***, Messina A, Dunn-Meynell AA, Balland E, Lacombe A, Mazur D, Carmeliet P, Bouret SG, Prevot V[#], Dehouck B. Tanycytic VEGF-A boosts blood-hypothalamus barrier plasticity and access of metabolic signals to the arcuate nucleus in response to fasting. *Cell Metabolism*, 17(4): 607-617 (2013). IF=16.7; C=173.
86. Henze AT, Leite de Oliveira R, and **Mazzone M**[#]. Prolyl Hydroxylases in fight or flight. *Mol Med Ther*, 1:1 (2012). *Invited Editorial*; IF=4.5; C=1
87. Kiss J, Mollenhauer M, Walmsley S, Kirchberg J, Radhakrishnan P, Niemietz T, Steinert G, Whyte M, Carmeliet P, **Mazzone M**, Weitz J, and Schneider M. Loss of the oxygen sensor PHD3 augments macrophage-mediated systemic inflammatory responses in mice. *Journal of Immunology*, 189(4): 1955-1965 (2012). IF=5.5; C=49.
88. Leite de Oliveira R, Deschoemaeker S, Henze AT, Debackere K, Finisguerra V, Takeda Y, Roncal C, Dettori D, Tack E, Jönsson Y, Veschini L, Peeters A, Anisimov A, Hofmann M, Alitalo K, Baes M, D’hooge J, Carmeliet P, and **Mazzone M**[#]. Gene-targeting of *Phd2* improves tumor response to chemotherapy and prevents side-toxicity. *Cancer Cell*, 22(2): 263-277 (2012). *Featured article*; IF=24.7; C=85.
89. Tejpar S, Prenen H, and **Mazzone M**. Overcoming resistance to antiangiogenic therapies. *Invited Review; The Oncologist*, 17(8): 1039-1050 (2012). IF=4.1; C=43.
90. Lambrechts D, Claes B, Delmar P, Reumers J, **Mazzone M**, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, and Van Cutsem E. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. *Lancet Oncology*, 13: 724-133 (2012). IF=25.1; C=142.
91. Tugues S, Honjo S, König C, Noguer O, Hedlund M, Botling J, Deschoemaeker S, Wenes M, Rolny C, Jahn-Dechent W, **Mazzone M**, and Claesson-Welsh L. Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization. *Cancer Research*, 72(8): 1953-1963 (2012). IF=8.7; C=24.
92. Squadrito ML, Pucci F, Moi D, Gilfillan G, Magri L, Casazza A, Ranghetti A, **Mazzone M**, Lyle R, Naldini L, and De Palma M. miR-511-3p modulates genetic programs of tumor associated macrophages. *Cell Reports*, 1: 141-154 (2012). IF= 7.2 C=132.
93. Casazza A, Kigel B, Maione F, Capparuccia L, Kessler O, Giraudo E, **Mazzone M**, Neufeld G, and Tamagnone L. Tumor growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin-3E isoform.

EMBO Mol Med, 4(3): 234-250 (2012). IF=7.8; C=58.

94. Takeda Y, Costa S, Delamarre E, Roncal C, Leite De Oliveira R, Squadrito ML, Finisguerra V, Deschoemaeker S, Bruyère F, Wenes M, Hamm A, Serneels J, Magat J, Bhattacharyya T, Anisimov A, Jordan B, Alitalo K, Maxwell P, Gallez B, Zhuang Z, Saito Y, Simons M, De Palma M, and **Mazzone M**[#]. Macrophage skewing by PHD2 haploinsufficiency prevents ischemia by inducing arteriogenesis. *Nature*, 479(7371): 122-116 (2011). IF=36.3; C=196.
95. Tamagnone L and **Mazzone M**. Semaphorin signals on the road of endothelial tip cells. *Invited Commentary; Dev Cell*, 21(2): 189-190 (2011). IF=14.0; C=16.
96. De Bock K, **Mazzone M**, and Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? *Nature Reviews Clinical Oncology*, 8: 393-404 (2011). *Invited Review*; IF=12.0; C=182.
97. Leite de Oliveira R, Hamm A, and **Mazzone M**[#]. Growing tumor vessels: More than one way to skin a cat - Implications for angiogenesis targeted cancer therapies. *Molecular Aspects of Medicine*, 32(2): 71-87 (2011). *Invited Review*; IF=10.0; C=44.
98. Casazza A, Fu X, Johansson I, Capparuccia L, Andersson F, Giustacchini A, Squadrito ML, Venneri MA, **Mazzone M**, Larsson E, Carmeliet P, De Palma M, Naldini L, Tamagnone L, and Rolny C. Systemic and targeted delivery of Sema3A inhibits tumor angiogenesis and tumor progression. *Arterioscler Thromb Vasc Biol*, 31(4): 741-749 (2011). IF=6.4; C=73.
99. Rolny C*, **Mazzone M***, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Åkerud P, De Mol M, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, and Carmeliet P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. *Cancer Cell*, 19(1): 31-44 (2011). IF=26.6; C=431.
100. Coenegrachts L, Maes C, Torrekens S, Van Looveren R, **Mazzone M**, Guise TA, Bouillon R, Carmeliet P, and Carmeliet G. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. *Cancer Research*, 70(16): 6537-6547 (2010). IF=8.2; C=37.
101. Storkebaum E, Ruiz de Almodovar C, Meens M, Zacchigna S, **Mazzone M**, Vanhoutte G, Vinckier S, Poesen K, Lambrechts D, Janssen JMR, Fazzi G, Schiffers PM, Rohrer H, Van der Linden A, De Mey J, and Carmeliet P. Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery. *Circulation*, 122(3): 273-181 (2010). IF=14.4; C=32.
102. Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, Rolny C, Christensen C, Bertotti A, Sarotto I, Risio M, Trusolino L, Weitz J, Schneider M, **Mazzone M**[#], Comoglio PM, and Tamagnone L[#]. Sema3E-PlexinD1 signaling drives cancer cell invasiveness and metastatic spreading in vivo. *The Journal of clinical investigation*, 120(8): 2684-2698 (2010). IF=14.2; C=112.
103. Geudens I, Herpers R, Hermans K, Segura I, Ruiz de Almodovar C, Bussmann J, De Smet F, Vandeveldel W, Hogan BM, Siekmann A, Claes F, Moore JC, Pistocchi AS, Loges S, **Mazzone M**, Mariggi G, Bruyère F, Cotelli F, Kerjaschki D, Noël A, Foidart JM, Gerhardt H, Ny A, Langenberg T, Lawson ND, Duckers HJ, Schulte-Merker S, Carmeliet P, and Dewerchin M. Role of Delta-like-4/Notch in the formation and wiring of the lymphatic network in zebrafish. *Arterioscler Thromb Vasc Biol*, 30(9): 1682-1683 (2010). IF=7.2; C=82.
104. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres JO, Van Bergen T, Cuervo H, Xiao WH, Le Henaff C, Buysschaert I, Kharabi B, Geerts A, Schomber T, Bonnin P, Lambert V, Haustreaete J, Zacchigna S, Rakic JM, Jiménez W, Noël A, Giacca M, Colle I, Foidart J, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell P, Vinores S, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H, Christofori G, **Mazzone M**, Detmar M, Collen D, and Carmeliet P. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. *Cell*, 141(1): 178-190 (2010). IF=32.4; C=190.
105. Schneider M, Van Geyte K, Fraisl P, Kiss J, Aragonés J, **Mazzone M**, Mairbäurl H, Debock K, Ho Jeung N, Mollenhauer M, Georgiadou M, Bishop T, Roncal C, Sutherland A, Jordan B, Gallez B, Weitz J, Harris RA, Maxwell P, Baes M, Ratcliffe P, and Carmeliet P. Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. *Gastroenterology*, 138(3): 1143-1154 (2010). IF=12.0; C=83.
106. Carmeliet P, De Smet F, Loges S, and **Mazzone M**. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. *Nature Reviews Clinical Oncology*, 6(6): 315-326 (2009). *Invited Review*; IF=10.8; C=135.
107. Ruiz de Almodovar C, Lambrechts D, **Mazzone M**, and Carmeliet P. Role and therapeutic potential of VEGF in

- the nervous system. *Physiological Reviews*, 89(2): 607-648 (2009). *Invited Review*; IF=37.7; C=256.
108. Loges S, **Mazzone M**, Hohensinner P, and Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. *Cancer Cell*, 5(3): 167-170 (2009). *Invited Review*; IF=25.3; C=304.
109. **Mazzone M**, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian Y, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragonés J, Luttun A, Wyns S, Debackere K, Jordan B, Pisacane A, Gallez B, Lampugnani MG, Dejana E, Simons M, Ratcliffe P, Maxwell P, and Carmeliet P. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. *Cell*, 36(5): 839-851 (2009). IF=31.2; C=521.
110. Fraisl P, **Mazzone M**, Schmidt T, and Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. *Dev Cell*, 16(2): 167-179 (2009). *Invited Review*; IF=13.4; C=243.
111. Fischer C, **Mazzone M**, Jonckx B, and Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? *Nature Rev Cancer*, 8(12): 942-956 (2008). *Invited Review*; IF=30.8; C=408.
112. Vigna E, Pacchiana G, **Mazzone M**, Chiriaco C, Fontani L, Basilico C, Pennacchietti S, and Comoglio PM. "Active" cancer immunotherapy by anti-Met antibody gene transfer. *Cancer Research*, 68(22): 9176-9183 (2008). IF=7.5; C=25.
113. **Mazzone M** and Carmeliet P. Drug discovery: a lifeline for suffocating tissues. *Invited Commentary; Nature*, 453(7199): 1194-1195 (2008). IF=31.4; C=13.
114. Rolny C, Capparuccia L, Casazza A, **Mazzone M**, Vallario A, Cignetti A, Medico E, Carmeliet P, Comoglio PM, and Tamagnone L. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. *The Journal of experimental medicine*, 205(5): 1155-1171 (2008). IF=14; C=68.
115. Takahara T, Xue F, **Mazzone M**, Yata Y, Nonome K, Kanayama M, Kawai K, Pisacane AM, Takahara S, Li XK, Comoglio PM, Sugiyama T, and Michieli P. Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. *Hepatology*, 47(6): 2010-2025 (2008). IF=11.4; C=13.
116. Aragonés J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, **Mazzone M**, Dirckx R, Zacchigna S, Lemieux H, Jeoung NH, Lambrechts D, Bishop T, Lafuste P, Diez-Juan A, Harten SK, Van Noten P, De Bock K, Willam C, Tjwa M, Grosfeld A, Navet R, Moons L, Vandendriessche T, Deroose C, Wijeyekoon B, Nuyts J, Jordan B, Silasi-Mansat R, Lupu F, Dewerchin M, Pugh C, Salmon P, Mortelmans L, Gallez B, Gorus F, Buyse J, Sluse F, Harris RA, Gnaiger E, Hespel P, Van Hecke P, Schuit F, Van Veldhoven P, Ratcliffe P, Baes M, Maxwell P, and Carmeliet P. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. *Nature Genetics*, 40(2): 170-180 (2008). IF=30.3; C=345.
117. Fischer C, Jonckx B, **Mazzone M**, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, and Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. *Cell*, 131(3): 463-475 (2007). IF=29.9; C=607.
118. **Mazzone M**, Ruiz de Almodovar C, and Carmeliet P. Building in resistance to endothelial cell death. *Nature Genetics*, 39(11): 1308-1309 (2007). *Invited Commentary*; IF=25.6; C=2.
119. Arena S, Pisacane A, **Mazzone M**, Comoglio PM, and Bardelli A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. *P Natl Acad Sci USA*, 104(27): 11412-11417 (2007). IF=9.6; C=28.
120. Bardella C, Dettori D, Olivero M, Coltella N, **Mazzone M**, and Di Renzo MF. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. *Clin Cancer Res*, 13(7): 2191-2198 (2007). IF=6.3; C=25.
121. **Mazzone M** and Comoglio PM. The Met pathway: master switch and drug target in cancer progression. *Review; Faseb J*, 20(10): 1611-1621 (2006). IF=6.7; C=105.
122. Petrelli A, Circosta P, Granziero L, **Mazzone M**, Pisacane A, Fenoglio S, Comoglio PM, and Giordano S. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. *P Natl Acad Sci USA*, 103(13): 5090-5095 (2006). IF=9.6; C=130.
123. **Mazzone M**, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, and Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. *The Journal of Clinical Investigation*, 114(10): 1418-1432 (2004). IF=14.2; C=83.
124. Michieli P*, **Mazzone M***, Basilico C, Cavassa S, Sottile A, Naldini L, and Comoglio PM. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. *Cancer Cell*, 6(1): 61-73 (2004). IF=18.1; C=233.

125. Pennacchietti S, Michieli P, Galluzzo M, **Mazzone M**, Giordano S, and Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. *Cancer Cell*, 3(4): 347-361 (2003). IF=18.9; C=968.
126. Michieli P, Cavassa S, Basilico C, De Luca A, **Mazzone M**, Asti C, Chiusaroli R, Guglielmi M, Bossu P, Colotta F, Caselli G, and Comoglio PM. An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. *Nature Biotechnology*, 20(5): 488-495 (2002). IF=12.8; C=22.

UNDER REVIEW

- Amorim R, Pecqueux M, Varamo C, Prenen F, Van Haele M, Rouhi P, Goveia J, Benkheil M, Berardi E, Thienpont B, Di Matteo M, Roskams T, Carmeliet P, Topal B, **Mazzone M**[#]. Cytidine deaminase blockade overcomes immunosuppression and restores response to immunotherapy in pancreatic cancer. *Cell*
- Oliveira AI^{*}, Celus W^{*}, Landeloos E, Serneels J, Kohler A, Flamand V, Garg A, Marine JC, Costa BM, **Mazzone M**[#]. (2020) PlxnA4 mediates cytotoxic T cell exclusion in cancer. *Science Translational Medicine*
- Menga A, Gissi B, De Grassi A, Laera L, Vegliante MC, Campanella A, Canton M, Loizzi V, Cormio G, **Mazzone M**^{#,*}, Castegna A. Release of N-acetylaspartate by glutaminolytic ovarian cancer cells highjacks pro-tumoral macrophages in synergy with IL10. *Cancer Research*
- Virga F, Henze AT, Cappellesso F, Stijlemans B, Trotta R, Mirchandani J, Vandewalle J, Van Audenaerde J, Griffa A, Ordo F, Prenen H, Van der Merwe S, Martelli F, Laoui D, almsley SR, Libert C, Corbet C, Van Ginderachter J, Ivan M, Taverna D^{*}, **Mazzone M**^{*}. Mir-210 induction by host-pathogen interaction modulates macrophage metabolism and response determining disease outcome. *Nature Immunology*
- Coppo R^{*}, Orso^{*} F, Virga F, Dalmasso A, Baruffaldi D, Dettori D, Quirico L, Grassi E, Nie L, Provero P, Valdembri D, Serini G, Sadeghi MM, **Mazzone M**^{#,*}, Taverna D^{#,*}. ESDN/DCBLD2/CLCP1 inhibits melanoma progression by blocking E-selectin expression on endothelial cell. *Nature Communications*.
- Orso F, Virga F, Dettori D, Paradzik M, Dalmasso A, Bolli E, Cavallo F, Savino A, Forni M, Salmena L, Pandolfi PP, **Mazzone M**^{#,*}, Taverna D^{#,*}. Stromal miR-214 contributes to tumor dissemination . *Nature Communications* -

IN PREPARATION

- Cappellesso F, Virga F, Agra Amorim R, Neveu M-A, Gallez B, Jordan B, Joudiou N, Mignon L, Reshkin S, Caroppo R, Taverna D, **Mazzone M**. Expression of the metabolite transporter SLC4A4 in pancreatic cancer cells promotes immune escape and resistance to immunotherapy. *Nature Cell Biology – submission ongoing*

BOOK CHAPTERS

- ‘Molecular Mechanisms of Angiogenesis: From Ontogenesis to Oncogenesis’, edited by Feige JJ, Pagès G and Soncin F. ‘Endothelial cell reactions to oxygen: implications for cancer’ by Leite de Oliveira R and **Mazzone M**. Springer Publishing (published in 2014).
- ‘Molecular Mechanisms of Angiogenesis’, edited by Schmidt MHH and Liebner S. ‘Oxygen signaling in physiological and pathological angiogenesis. Vascular Signaling in Health and Disease’ by Henze AT and **Mazzone M**. Springer Publishing (published in 2015).